Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Standardized Mite, Dermatophagoides pteronyssinus
Overview
What is Standardized Mite, Dermatophagoides pteronyssinus?
DESCRIPTION
D. farinae
D. pteronyssinus
INGREDIENTS:
standardized quality procedures
no material of human origin.
D. farinae
D. pteronyssinus
Saccharomyces sp.
50
1,2,3,4,5,16
What does Standardized Mite, Dermatophagoides pteronyssinus look like?
What are the available doses of Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No records found.
What should I talk to my health care provider before I take Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No records found
How should I use Standardized Mite, Dermatophagoides pteronyssinus?
INDICATIONS AND USAGE
D. farinae
D. pteronyssinus
PRICK-PUNCTURE TESTING:
Smaller, less conclusive reactions may be considered positive in conjunction with a definitive history of symptoms on exposure to the mite allergen. The more sensitive the patient the higher the probability that he/she will have symptoms related to the exposure of the offending allergen. Hence, the importance of a good patient history. Less sensitive individuals can be tested intradermally with an appropriately diluted extract. A clinical study using the same patients with positive prick-puncture test (10) using the , has demonstrated the following: Skin test by prick-puncture test using Standardized Mite, 10,000 AU/ml was performed in 10 patients. The mean sum of erythema diameter was 76.6 mm (Range 45-104 mm). Skin test by prick-puncture test using Standardized Mite, 10,000 AU/ml in 10 patients, the mean sum of erythema diameter was 74.7 mm (Range 43-109 mm).
*C = Concentration
SINGLE DILUTION INTRADERMAL TESTING:
INTRADERMAL TESTING–SKIN ENDPOINT TITRATION:
D. farinae Mite
D. pteronyssinus
DOSAGE AND ADMINISTRATION
physician must proceed cautiously in the treatment of the highly sensitive patient who develops large local or systemic reactions
Maintenance dose potency must be established by the physician's clinical observation and experience
7
8,12
6,13
What interacts with Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No Records found
What are the warnings of Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No Records found
What are the precautions of Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No Records found
What are the side effects of Standardized Mite, Dermatophagoides pteronyssinus?
Sorry No records found
What should I look out for while using Standardized Mite, Dermatophagoides pteronyssinus?
CONTRAINDICATIONS
WARNINGS
IN THESE CASES BOTH THE POTENCY FOR SKIN TESTS AND THE ESCALATION OF THE TREATMENT DOSE MUST BE ADJUSTED TO THE PATIENT'S SENSITIVITY TOLERANCE.
changing immunotherapy from an unstandardized to an AU/ml standardized allergenic extract
dose reduced to 75%.
What might happen if I take too much Standardized Mite, Dermatophagoides pteronyssinus?
OVERDOSAGE
4
How should I store and handle Standardized Mite, Dermatophagoides pteronyssinus?
Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP] .HOW SUPPLIED Dermatophagoides farinaeDermatophagoides pteronyssinusHOW SUPPLIED Dermatophagoides farinaeDermatophagoides pteronyssinusHOW SUPPLIED Dermatophagoides farinaeDermatophagoides pteronyssinus
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
CLINICAL PHARMACOLOGY
3,5
10,14,15
Non-Clinical Toxicology
CONTRAINDICATIONSWARNINGS
IN THESE CASES BOTH THE POTENCY FOR SKIN TESTS AND THE ESCALATION OF THE TREATMENT DOSE MUST BE ADJUSTED TO THE PATIENT'S SENSITIVITY TOLERANCE.
changing immunotherapy from an unstandardized to an AU/ml standardized allergenic extract
dose reduced to 75%.
PRECAUTIONS
Antihistamines.
Corticosteroids.
Theophylline.
Beta-adrenergic agents.
Cromolyn.
Other drugs.
Specific Immunotherapy.
13,14
11
17,18,19,20,21,22
23
23
23
23
23
23
23
23
23
1
1
1
1
1
2
2
ADVERSE REACTIONS
Patients receiving beta-blockers may not be responsive to epinephrine or inhaled bronchodilators.
beta-blockers
24
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).